FY2025 EPS Estimates for IN8bio Boosted by Zacks Small Cap

IN8bio, Inc. (NASDAQ:INAB) – Stock analysts at Zacks Small Cap boosted their FY2025 earnings per share (EPS) estimates for shares of IN8bio in a note issued to investors on Monday, March 17th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will earn ($0.17) per share for the year, up from their previous forecast of ($0.19). The consensus estimate for IN8bio’s current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for IN8bio’s FY2026 earnings at ($0.18) EPS.

IN8bio (NASDAQ:INAB) last announced its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.03.

Separately, HC Wainwright cut their price objective on IN8bio from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, March 14th.

IN8bio Price Performance

INAB stock opened at $0.24 on Thursday. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $19.17 million, a PE ratio of -0.31 and a beta of 0.03. IN8bio has a 12-month low of $0.21 and a 12-month high of $1.74. The business’s fifty day moving average price is $0.27 and its 200 day moving average price is $0.29.

Institutional Investors Weigh In On IN8bio

Institutional investors and hedge funds have recently modified their holdings of the company. BIOS Capital Management LP purchased a new stake in IN8bio during the 4th quarter worth about $2,212,000. Franklin Resources Inc. purchased a new stake in IN8bio during the 4th quarter worth about $1,465,000. Alyeska Investment Group L.P. increased its holdings in IN8bio by 1,064.5% during the 4th quarter. Alyeska Investment Group L.P. now owns 5,063,291 shares of the company’s stock worth $1,302,000 after purchasing an additional 4,628,482 shares during the period. AIGH Capital Management LLC increased its holdings in IN8bio by 269.7% during the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after purchasing an additional 4,517,227 shares during the period. Finally, Sigma Planning Corp increased its holdings in IN8bio by 22.3% during the 4th quarter. Sigma Planning Corp now owns 1,041,380 shares of the company’s stock worth $268,000 after purchasing an additional 190,100 shares during the period. Hedge funds and other institutional investors own 92.05% of the company’s stock.

IN8bio Company Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.